Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $46.02, for a total transaction of $690,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.20, for a total transaction of $1,011,271.20.
• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.00, for a total transaction of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total transaction of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00.

Maze Therapeutics Stock Up 0.4%

Maze Therapeutics stock traded up $0.17 during trading on Wednesday, hitting $48.14. The stock had a trading volume of 588,235 shares, compared to its average volume of 434,867. The stock’s 50 day moving average is $41.28 and its two-hundred day moving average is $29.58. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $48.94. The stock has a market cap of $2.32 billion and a price-to-earnings ratio of -2.30.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors have recently added to or reduced their stakes in MAZE. CWM LLC purchased a new stake in shares of Maze Therapeutics in the 2nd quarter valued at about $28,000. GF Fund Management CO. LTD. purchased a new position in shares of Maze Therapeutics during the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. increased its position in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Maze Therapeutics during the third quarter valued at approximately $52,000.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on MAZE shares. HC Wainwright reaffirmed a “buy” rating on shares of Maze Therapeutics in a report on Wednesday, January 28th. Guggenheim restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Friday, December 19th. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Wedbush boosted their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, January 25th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.